Thera-SAbDab

ANDECALIXIMAB

>   Structural Summary
TherapeuticAndecaliximab
TargetMMP9
Heavy ChainQVQLQESGPGLVKPSETLSLTCTVSGFSLLSYGVHWVRQPPGKGLEWLGVIWTGGTTNYNSALMSRFTISKDDSKNTVYLKMNSLKTEDTAIYYCARYYYGMDYWGQGTLVTVSS
Light ChainDIQMTQSPSSLSASVGDRVTITCKASQDVRNTVAWYQQKPGKAPKLLIYSSSYRNTGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQHYITPYTFGGGTKVEIK
100% seqID Fv Structure5th9 [Fvs: HL, IM, JN]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedGilead Sciences
Conditions Approvedna
Conditions ActiveGastric cancer, Solid tumours, Glioblastoma
Conditions DiscontinuedChronic obstructive pulmonary disease, Crohn's disease, Cystic fibrosis, Rheumatoid arthritis, Ulcerative colitis
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]